Biohaven (BHVN) Return on Capital Employed (2022 - 2026)
Biohaven's (BHVN) quarterly Return on Capital Employed came in at 160.81% in Q1 2026, up 8677.0% year-on-year from 1.83% in Q1 2025, and up 32.18% quarter-over-quarter from 237.12% in Q4 2025.
Biohaven (BHVN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Biohaven has disclosed Return on Capital Employed across 5 years of filings, most recently posting 160.81% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 160.81%, up 8677.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 160.81% (up 8677.0% YoY), and the FY2025 annual result was 178.6%, up 3731.0% from the prior year.
- Return on Capital Employed came in at 160.81% for Q1 2026 at Biohaven, up from 237.12% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 95.38% in Q2 2023 to a low of 247.57% in Q1 2025.
- The 5-year median for Return on Capital Employed is 197.33% (2022), against an average of 178.54%.
- Across the five-year window, Return on Capital Employed tumbled 13148 bps in 2024 and surged 8677 bps in 2026, its largest moves.
- Biohaven's Return on Capital Employed stood at 183.98% in 2022, then jumped by 40 bps to 111.08% in 2023, then tumbled by 95 bps to 216.63% in 2024, then retreated by 9 bps to 237.12% in 2025, then surged by 32 bps to 160.81% in 2026.
- The last three Return on Capital Employed figures came in at 160.81% (Q1 2026), 237.12% (Q4 2025), and 216.11% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Biohaven | 1.62 Bn | 1.27 Bn | - | -160.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -160.81% |
| Dec 31, 2025 | -237.12% |
| Sep 30, 2025 | -216.11% |
| Jun 30, 2025 | -210.69% |
| Mar 31, 2025 | -247.57% |
| Dec 31, 2024 | -216.63% |
| Sep 30, 2024 | -215.30% |
| Jun 30, 2024 | -226.86% |
| Mar 31, 2024 | -142.77% |
| Dec 31, 2023 | -111.08% |
| Sep 30, 2023 | -129.59% |
| Jun 30, 2023 | -95.38% |
| Mar 31, 2023 | -105.66% |
| Dec 31, 2022 | -183.98% |